A phase II trial is currently underway to investigate the safety and efficacy of adding etoposide to BV+CHP followed by BV consolidation in patients with CD30‐positive PTCL [38]. This evidence concerns the gene TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma.